1. aged below 21 years old 2. female who is pregnant or breast-feeding 3. with the following conditions, but not limited to: 1. known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months 2. child-pugh class c chronic liver disease 3. renal insufficiency with an estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73m2 calculated by the ckd-epi formula 4. suspected or confirmed active bacterial, fungal or mycobacterial infection 4. history of any allergic reaction to monoclonal antibodies 5. currently enrolled in another covid-19 investigational drug study 6. previously enrolled in a covid-19 investigational vaccine study 7. any medical condition, which in the opinion of the investigator, will compromise the safety of the patient

1. aged below 21 years old 2. female who is pregnant or breast-feeding 3. with the following conditions, but not limited to: 1. known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months 2. child-pugh class c chronic liver disease 3. renal insufficiency with an estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73m2 calculated by the ckd-epi formula 4. suspected or confirmed active bacterial, fungal or mycobacterial infection 4. history of any allergic reaction to monoclonal antibodies 5. currently enrolled in another covid-19 investigational drug study 6. previously enrolled in a covid-19 investigational vaccine study 7. any medical condition, which in the opinion of the investigator, will compromise the safety of the patient

aged below 21 years old female who is pregnant or breast-feeding with the following conditions, but not limited to: known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months child-pugh class c chronic liver disease renal insufficiency with an estimated glomerular filtration rate (egfr) < 30 ml/min/1.73m2 calculated by the ckd-epi formula suspected or confirmed active bacterial, fungal or mycobacterial infection history of any allergic reaction to monoclonal antibodies currently enrolled in another covid-19 investigational drug study previously enrolled in a covid-19 investigational vaccine study any medical condition, which in the opinion of the investigator, will compromise the safety of the patient

aged below 21 years old female who is pregnant or breast-feeding with the following conditions, but not limited to: known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months child-pugh class c chronic liver disease renal insufficiency with an estimated glomerular filtration rate (egfr) < 30 ml/min/1.73m2 calculated by the ckd-epi formula suspected or confirmed active bacterial, fungal or mycobacterial infection history of any allergic reaction to monoclonal antibodies currently enrolled in another covid-19 investigational drug study previously enrolled in a covid-19 investigational vaccine study any medical condition, which in the opinion of the investigator, will compromise the safety of the patient

1. aged below 21 years old 2. female who is pregnant or breast-feeding 3. with the following conditions, but not limited to: 1. known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months 2. child-pugh class c chronic liver disease 3. renal insufficiency with an estimated glomerular filtration rate (egfr) < 30 ml/min/1.73m2 calculated by the ckd-epi formula 4. suspected or confirmed active bacterial, fungal or mycobacterial infection 4. history of any allergic reaction to monoclonal antibodies 5. currently enrolled in another covid-19 investigational drug study 6. previously enrolled in a covid-19 investigational vaccine study 7. any medical condition, which in the opinion of the investigator, will compromise the safety of the patient

1. aged below 21 years old 2. female who is pregnant or breast-feeding 3. with the following conditions, but not limited to: 1. known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months 2. child-pugh class c chronic liver disease 3. renal insufficiency with an estimated glomerular filtration rate (egfr) < 30 ml/min/1.73m2 calculated by the ckd-epi formula 4. suspected or confirmed active bacterial, fungal or mycobacterial infection 4. history of any allergic reaction to monoclonal antibodies 5. currently enrolled in another covid-19 investigational drug study 6. previously enrolled in a covid-19 investigational vaccine study 7. any medical condition, which in the opinion of the investigator, will compromise the safety of the patient